IRIS
Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.388
NA - Nord America 5.321
SA - Sud America 1.654
EU - Europa 826
AF - Africa 160
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 15.367
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.094
SG - Singapore 4.856
BR - Brasile 1.359
CN - Cina 950
VN - Vietnam 772
HK - Hong Kong 238
IT - Italia 205
AR - Argentina 119
GB - Regno Unito 107
CA - Canada 102
IN - India 90
BD - Bangladesh 89
DE - Germania 86
MX - Messico 84
FR - Francia 80
ZA - Sudafrica 63
IQ - Iraq 57
EC - Ecuador 51
PL - Polonia 42
ID - Indonesia 41
RU - Federazione Russa 39
ES - Italia 36
JP - Giappone 36
NL - Olanda 34
TR - Turchia 31
PK - Pakistan 27
UA - Ucraina 26
FI - Finlandia 25
CO - Colombia 23
VE - Venezuela 23
SE - Svezia 22
PY - Paraguay 21
MA - Marocco 20
MY - Malesia 19
UY - Uruguay 19
CL - Cile 18
UZ - Uzbekistan 18
AE - Emirati Arabi Uniti 17
EG - Egitto 17
CZ - Repubblica Ceca 16
DZ - Algeria 16
PH - Filippine 16
SA - Arabia Saudita 16
KE - Kenya 15
LT - Lituania 15
NP - Nepal 14
IE - Irlanda 12
JM - Giamaica 12
JO - Giordania 12
TN - Tunisia 12
AU - Australia 11
AT - Austria 10
BO - Bolivia 10
KZ - Kazakistan 10
AL - Albania 9
PE - Perù 9
PS - Palestinian Territory 9
CH - Svizzera 8
CR - Costa Rica 8
OM - Oman 8
IL - Israele 7
KR - Corea 7
DO - Repubblica Dominicana 6
AZ - Azerbaigian 5
BE - Belgio 5
GR - Grecia 5
LB - Libano 5
NO - Norvegia 5
RO - Romania 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
BA - Bosnia-Erzegovina 4
KG - Kirghizistan 4
KW - Kuwait 4
NG - Nigeria 4
PT - Portogallo 4
BH - Bahrain 3
CI - Costa d'Avorio 3
CY - Cipro 3
ET - Etiopia 3
HR - Croazia 3
IR - Iran 3
LK - Sri Lanka 3
MD - Moldavia 3
RS - Serbia 3
SI - Slovenia 3
TW - Taiwan 3
BG - Bulgaria 2
BY - Bielorussia 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
HN - Honduras 2
HU - Ungheria 2
KH - Cambogia 2
LV - Lettonia 2
MM - Myanmar 2
NZ - Nuova Zelanda 2
Totale 15.343
Salva come PNG Salva come JPEG
Città #
Singapore 1.899
San Jose 1.095
Ashburn 980
The Dalles 848
Dallas 450
Shanghai 335
Beijing 281
Ho Chi Minh City 279
Hong Kong 224
Hanoi 169
Santa Clara 152
São Paulo 121
Boardman 110
Los Angeles 99
New York 75
Rio de Janeiro 46
Seattle 41
Mexico City 39
Da Nang 37
Belo Horizonte 36
Johannesburg 34
Warsaw 34
Orem 33
Tokyo 30
Buffalo 29
Chandler 29
Haiphong 28
Brasília 27
Council Bluffs 26
London 26
Milan 26
Montreal 26
Chicago 24
Dhaka 24
Helsinki 23
Phoenix 23
Toronto 23
Brooklyn 22
Curitiba 21
Guayaquil 20
Hải Dương 20
Atlanta 18
Boston 18
Campinas 18
Ribeirão Preto 18
San Francisco 18
Baghdad 17
Charlotte 17
Amsterdam 16
Montevideo 16
Porto Alegre 16
Stockholm 16
Rome 15
Tashkent 15
Ankara 14
Assago 14
Cape Town 14
Goiânia 14
Manchester 14
Paris 14
Quito 14
Frankfurt am Main 13
Hillsboro 13
Wilmington 13
Asunción 12
Chennai 12
Munich 12
Sorocaba 12
Amman 11
Biên Hòa 11
Buenos Aires 11
Caxias do Sul 11
Denver 11
Dublin 11
New Delhi 11
Reston 11
Thái Nguyên 11
Bắc Ninh 10
Cairo 10
Kingston 10
Lauterbourg 10
Recife 10
Salvador 10
Aracaju 9
Campo Grande 9
Hangzhou 9
Indaiatuba 9
Joinville 9
Nairobi 9
Naples 9
Poplar 9
Santo André 9
Santos 9
Bauru 8
Bologna 8
Brno 8
Can Tho 8
Erbil 8
Kuala Lumpur 8
Mumbai 8
Totale 8.572
Salva come PNG Salva come JPEG
Nome #
Gemcitabine is ineffective in recurrent, preirradiated cervical cancer 184
Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma 168
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 142
Morbidity And Complication Of Minimally Invasive Staging For Apparent Early-Stage Epithelial Ovarian Cancer: A Preliminary Analysis Of REMISSION Study 122
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial 91
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 89
Pembrolizumab for locally advanced cervical cancer - Authors' reply 89
Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial 83
Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer 82
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 78
Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey 76
Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies 76
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 74
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 74
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer 73
3D vision improves outcomes in early cervical cancer treated with laparoscopic type B radical hysterectomy and pelvic lymphadenectomy 70
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group 69
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 66
A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses 65
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer 64
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study 63
Adoptive immunotherapy with cytokine-induced killer cells generated with a new GMP-grade protocol 63
A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy 62
KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer? 62
When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer 61
A critical assessment on the role of sentinel node mapping in endometrial cancer 61
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study 60
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 60
Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors 60
Peritoneal cytology as prognostic factor in cervical cancer 59
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial 59
Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience 58
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial 58
[Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.] 58
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) 57
Advanced ovarian cancer: Omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor 57
Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. 57
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis 56
Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment 56
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* 56
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy 55
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 55
Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: progress toward a more personalized approach 54
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* 54
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial 54
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 54
Nomogram-based prediction of cervical dysplasia persistence/recurrence 53
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms 53
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 53
Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study 52
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib 52
Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy" 52
"Tumori della vulva e della vagina" 52
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile 52
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) 52
Trabectedin as a chemotherapy option for patients with BRCA deficiency 52
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL) 51
Advances in laparoscopic surgery for cervical cancer 51
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer 51
Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease 51
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04) 51
Celecoxib plus cartioplatin in heavily pre-treated patients with recurrent ovarian carcinoma: Preliminary results of a Phase II study 50
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial 50
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial 50
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 50
Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery 50
Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience 49
Advanced vulvar carcinoma: Is it worth operating? A perioperative management protocol for radical and reconstructive surgery 49
Bulky mesonephric adenocarcinoma of the uterine cervix treated with neoadjuvant chemotherapy and radical surgery: report of the first case 49
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer 49
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 49
Uterine serous carcinoma 49
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial 48
Surgical Management and Prognostic Factors of Vulvovaginal Melanoma 48
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer 48
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study 48
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer 48
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 48
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 48
Navigating the Landscape of Resistance Mechanisms in Antibody-Drug Conjugates for Cancer Treatment 47
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial 47
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer - A Multicentre Italian Trial in Ovarian cancer (MITO-5) study 47
Survival with Cemiplimab in Recurrent Cervical Cancer 47
Extraperitoneal Robotic-Assisted Para-Aortic Lymphadenectomy in Gynecologic Cancer Staging: Current Evidence 47
Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses 47
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance 46
Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features 46
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS) 46
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study 46
TERAPIA PRIMARIA DEL CARCINOMA DELL'ENDOMETRIO: CHEMIOTERAPIA 46
Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis 46
Do you agree with populations that have been defined as 'noncandidates' to receiving platinum? 45
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 44
Fertility sparing surgery in early stage epithelial ovarian cancer 44
Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts 44
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary 44
Class II versus Class III radical hysterectomy in early cervical cancer: an observational study in a tertiary center 44
Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy 44
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer 43
Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis 42
Totale 5.954
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.795
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.795
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213 0 0 0 0 0 0 0 0 0 0 0 3
2021/202219 2 0 0 2 0 0 0 2 1 2 4 6
2022/202387 13 2 7 13 2 8 0 11 16 9 5 1
2023/2024907 6 5 11 3 0 8 2 0 271 21 187 393
2024/20254.263 82 108 147 44 17 297 336 248 683 1.105 623 573
2025/202610.465 1.630 779 648 982 378 614 2.940 520 566 730 413 265
Totale 15.767